Recently, irbesartan, an angiotensin type 1 receptor antagonist used for treating hypertension, was shown to overcome Gem resistance in PDAC models by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. Here, YAP1 is linked to hypertensive disorder.